Amicus Therapeutics Q4 Adj EPS $0.01 Beats $(0.06) Estimate, Sales $115.08M Beat $114.33M Estimate
Portfolio Pulse from Benzinga Newsdesk
Amicus Therapeutics reported Q4 adjusted earnings of $0.01 per share, surpassing the consensus estimate of $(0.06). Quarterly sales reached $115.08M, exceeding the $114.33M estimate and marking a 30.63% increase from the previous year.
February 28, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amicus Therapeutics exceeded Q4 earnings and sales forecasts, with a significant year-over-year revenue increase.
Beating both earnings and sales estimates, especially by a significant margin and showing a substantial year-over-year growth, typically leads to positive investor sentiment and could drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100